1701 Harbor Bay Parkway
About Singulex, Inc.
Singulex is the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex’s ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics. Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex is developing the Singulex Clinical Diagnostic System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. For further information, please visit www.singulex.com.
About Singulex’s Erenna Platform
Powered by Single Molecule Counting (SMC™) technology, Singulex’s Research-Use-Only Erenna® Immunoassay System’s ability to measure small changes in biomarkers such as cardiac troponin I and cytokines, and to monitor these changes over time, has expanded the clinical utility of established markers. The Erenna system helps power the discovery and development of innovative lab developed tests and treatments for chronic diseases such as cardiovascular disease, Alzheimer’s disease, oncology, rheumatoid arthritis and diabetes.
57 articles with Singulex
Singulex actively collaborated with cardiologists to understand the clinical value of measuring cardiac troponin at previously immeasurable levels in blood
Singulex Announces 510(K) Submission for the First Ultra-Sensitive Cardiac Troponin I (cTnI) Test Using Single Molecule Counting Technology
Singulex today announced it has filed a 510(k) pre-market notification submission with the FDA for its Singulex Clarity cTnI assay to run on the Singulex Clarity system.
Singulex Receives New, Broad Patent For Digital Detection Of Cardiac Troponin-I Or Cardiac Troponin-T For Coronary Artery Disease Rule-Out
Evaluations Of The Analytical Performance Of The Singulex Cardiac Troponin I Assay Used On Its Single Molecule Counting Technology Platform Demonstrates Ability To Improve Cardiovascular Disease Rule-Out
Ultra-Sensitive C. Difficile Assay In Development By Singulex Demonstrates Potential To Improve Diagnosis In Pilot Studies
Singulex Release: First Ultra-Sensitive Cardiac Troponin (cTnI) Test Using Single Molecule Counting Technology Receives CE Mark
Singulex Expands Collaboration With European Clinical Laboratories To Demonstrate Applications And Opportunity Of Sgx Clarity System
Singulex Release: Diagnostic Company Enters Into Collaboration With QIAGEN N.V. To Develop Companion Diagnostics
Singulex And Thermo Fisher Scientific Enter Into License And Supply Agreement To Bring Next Generation Immunodiagnostics To Sepsis And SIRS Diagnostics
Singulex Release: Study Demonstrates Cardiac Troponin Analysis Can Help Identify Heart Disease Risk And Guide Treatment
U.S. Patent Awarded To Singulex, Inc. For Expanded Use Of Biomarkers Troponin I And T To Detect Cardiac Health Status With Single-Molecule Methods
Singulex, Inc. Receives European Patent Expanding Use Of Biomarkers Troponin I And T To Detect Cardiac Health Status With High-Sensitivity Methods